Skip to content
Menu

Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $13

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $17 to $13.

Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $17 to $13.

Read at benzinga.com